Dear Editor, BH3-mimetic drugs that antagonize Bcl-2 family prosurvival proteins are effective against some cancers, particularly those with abnormally high expression of the prosurvival protein target.
Dear Editor, BH3-mimetic drugs that antagonize Bcl-2 family prosurvival proteins are effective against some cancers, particularly those with abnormally high expression of the prosurvival protein target. 1 Despite the recent success of BH3-mimetics targeting Bcl-2, Bcl-x L and Bcl-w, mechanism-based cell killing in vivo by targeting other important prosurvival proteins such as Mcl-1 or Bfl-1 has yet to be demonstrated. In the absence of small molecules targeting these prosurvival proteins, BH3-domain peptides, the prototypes for this class of drug, are useful because their binding specificity profile can be manipulated. 2, 3 Such peptides have been applied in in vitro studies to validate the targeting of particular prosurvival proteins in certain tumor types. 4, 5 However, in vivo applications require technically challenging chemical modifications of peptides, and while mouse xenograft models of virally-infected BH3 domainexpressing tumor cells can be used, this does not allow evaluation of effects of the ligand on normal tissues.
Here we have generated transgenic mice in which peptidebased BH3 ligands can be inducibly expressed to evaluate their effects in vivo and provide proof-of-principle for similaracting drugs. To achieve this we adapted a previously described strategy allowing FLP-recombinase-mediated insertion of an expression cassette at an frt 'landing pad' at the type I collagen (Col1a1) locus in mouse embryonic stem cells. 6 The cassette comprises sequences encoding a BH3-domain protein under control of a tetracycline (tet)-regulated element (TRE) promoter. To develop a system that is broadly applicable to BH3 domains with different specificities, we employed the Bim S BH3-only protein as a scaffold in which BH3 domains with different specificities could replace the native BH3 sequence (Figure 1a ). Bim S is an intrinsically unstructured protein that tolerates extensive mutation of its BH3 sequence, and Bim S BH3 chimeras display the prosurvival protein specificity profile of the replacement BH3 domain. 7 In this study we focussed on the BH3 domain of Bad because it targets the prosurvival proteins Bcl-2, Bcl-x L and Bcl-w. 7 Hence Bim S Bad expression should mimic the BH3-mimetics ABT-737 and ABT-263 that have been extensively studied in vivo. 1 We generated TRE-Bim S Bad transgenic mice and crossed them to mice expressing the rtTA (tet-on) transactivator under the control of the cytomegalovirus (CMV) promoter, which provides high-level expression in many tissues including blood. 8 Bitransgenic mice were then treated with doxycycline (Dox) to induce Bim S Bad expression (Figure 1a ). Western blot analysis verified Dox-inducible transgene expression in white blood cells of Bim S Bad; CMV-rtTA bitransgenic mice ( Figure 1b) . As ABT-737/263 induces thrombocytopenia in mice and humans due to antagonism of Bcl-x L , we measured platelet levels as a biomarker for functional expression of the ligand. 1 Notably, blood cell analysis of these mice revealed a significant reduction (~65% decrease) in platelet counts (Figure 1c and d) , a degree of thrombocytopenia comparable with that seen in patients administered with ABT-263. 9 Importantly, platelet counts rebounded to normal levels following removal of Dox for 7 days (Figure 1d ), illustrating the reversibility of the system. We also generated an additional transgenic mouse strain allowing inducible expression of a Bim S Bad construct possessing a BH3 sequence mutation (Bim S Bad mut ; Figure 1a ) that decreases its affinity for Bcl-x L by 440-fold (K D 8.5 nM versus o0.2 nM as measured by surface plasmon resonance). Induction of Bim S Bad mut expression (Figure 1b) did not alter blood cell or platelet counts (Figure 1d ), indicating that the thrombocytopenia observed in Bim S Bad mice is due to Bcl-x L inhibition. These data provide the first evidence that BH3-only proteins can be inducibly expressed in a mouse model, effectively mimicking at least one functional consequence (reduced platelet counts) seen in mice and humans treated with BH3-mimetic drugs of similar specificity. We envisage multiple applications for similarly engineered mice. For example, tet-regulated expression of different Bim S variants in mice could reveal toxicities associated with neutralization of their prosurvival protein targets (individually or in combination), and tissue-specific effects could be addressed by crossing onto mice where rtTA expression is driven by different promoters. Moreover, mice crossed to different tumor-prone models could provide in vivo evidence for the tumor-killing efficacy associated with different BH3 specificities not yet available through small molecule 
